Ublituximab reduces relapse rates and disability progression over 5 years in patients with relapsing multiple sclerosis.

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...

--TG Therapeutics, Inc., today announced updated data presentations including new six-year data from the ULTIMATE I& II Phase 3 trials evaluating BRIUMVI ® in patients with relapsing forms of multiple ...

TG Therapeutics, Inc. announced new data presentations for BRIUMVI® (ublituximab-xiiy) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, highlighting its efficacy for ...

A study found brain atrophy progresses more slowly with age in RRMS, highlighting the need to factor age into MS clinical ...

Please provide your email address to receive an email when new articles are posted on . This enduring CE multimedia web activity is based on a live satellite symposium held during the 2025 CMSC Annual ...

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...

- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...

Kesimpta is a prescription medication used to treat clinically isolated syndrome (CIS) and relapsing forms of multiple sclerosis (MS). Kesimpta comes as a solution inside single-dose prefilled ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...